Pippa S. Loupe

Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of high-frequency episodic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study

Marcelo E. Bigal, David W. Dodick, Alan M. Rapoport et al. · The Lancet Neurology · 2015 · 285 citations

Medicine, Neurology, Preventive Medicine +8

Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of chronic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study

Marcelo E. Bigal, Lars Edvinsson, Alan M. Rapoport et al. · The Lancet Neurology · 2015 · 260 citations

Medicine, Neurology, Preventive Medicine +9

TEV-48125 for the preventive treatment of chronic migraine

Marcelo E. Bigal, David W. Dodick, Abouch Valenty Krymchantowski et al. · Neurology · 2016 · 92 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +16

Mobilise-D insights to estimate real-world walking speed in multiple conditions with a wearable device

Cameron Kirk, Arne Küderle, M. Encarna Micó-Amigo et al. · Scientific Reports · 2024 · 71 citations · Full text

Education, Physical Medicine, Movement Analysis +16

A phase 1 study to assess the pharmacokinetics, safety, and tolerability of fremanezumab doses (225 mg, 675 mg and 900 mg) in Japanese and Caucasian healthy subjects

Orit Cohen‐Barak, Sivan Weiss, Michèle Rasamoelisolo et al. · Cephalalgia · 2018 · 54 citations

Pharmacy, Pharmacokinetics, Pharmacology +15